Stock N1BI34 NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Neurocrine Biosciences, Inc. Sao Paulo

Equities

N1BI34

BRN1BIBDR009

Market Closed - Sao Paulo
Other stock markets
 12:24:59 2024-06-28 EDT 		5-day change 1st Jan Change
38.68 BRL +3.64% Intraday chart for Neurocrine Biosciences, Inc. +5.45% +19.75%
06-13 Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM
06-05 Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
CI
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
CI
Neurocrine Biosciences, Inc. Announces Dr. Kyle Gano as Director, Effective October 11, 2024
CI
Neurocrine Biosciences Announces CEO Changes
CI
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis
CI
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
CI
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
CI
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
CI
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
CI
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024
CI
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell
MT
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q1 Revenue $515.3M, vs. Street Est of $512M
MT
Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q1 EPS $1.20, vs. Street Est of $1.29
MT
Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024
CI
Neurocrine Biosciences' Huntington's disease drug gets FDA approval
RE
FDA approves Neurocrine Biosciences' Huntington's disease drug
RE
Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules
CI
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
CI
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. N1BI34 Stock
  5. News Neurocrine Biosciences, Inc.
  6. Highlights